Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q3 CY2025, with sales up 38.5% year on year to $265.2 million. The company’s full-year revenue guidance of $967.5 million at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP loss of $0.39 per share was 20.3% above analysts’ consensus estimates.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Diagnostics company Guardant Health (NASDAQ:GH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 38.5% year on year to $265.2 million. The company’s full-year revenue guidance of $967.5 million at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP loss of $0.39 per share was 20.3% above analysts’ consensus estimates.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
Shares of diagnostics company Guardant Health (NASDAQ:GH)
jumped 1.6% in the morning session after the U.S. Food and Drug Administration (FDA) approved its Guardant360® CDx blood test as a companion diagnostic for Eli Lilly's new advanced breast cancer treatment, Inluriyo™.
Shares of diagnostics company Guardant Health (NASDAQ:GH)
jumped 5.2% in the morning session after the company announced a collaboration with Quest Diagnostics and provided an upbeat financial outlook at its investor day. The partnership aimed to make Guardant's Shield blood-based cancer screening test more widely available to physicians and patients in the United States. During its investor event, the company also revealed it accelerated its timeline for reaching cash flow breakeven by about 12 months.
